New clinical review provides the most comprehensive treatment guidelines for severe atopic dermatitis (eczema):

Researchers raise bar for successful management of severe atopic dermatitis

 

AURORA, Colorado, USA (Jan. 15, 2019) – A team of investigators from the University of Colorado College of Nursing at CU Anschutz Medical Campus and National Jewish Health has identified comprehensive guidelines for managing severe atopic dermatitis (AD), the most common form of eczema. The clinical management review was recently published in The Journal of Allergy and Clinical Immunology: In Practice.

„The FDA approval of biologic medication for treating moderate-to-severe AD has transformed the therapeutic landscape highlighting the need for comprehensive and clear guidelines,“ said Noreen Nicol, PhD, RN, Associate Professor in the College of Nursing at CU Anschutz Medical Campus. „Without comprehensive guidelines that analyze national and international findings, we risk clinicians skipping crucial conventional steps, such as wet-wrap therapy, that need to be utilized prior to initiating biologics.“

Atopic dermatitis affects up to 18 percent of children as well as seven percent of adults. As a chronic, relapsing disease, severe AD has a profound impact on the quality of life of patients and families. Recent studies reveal patients with severe cases report high itch frequency of up to 18 hours a day, sleep disturbance and borderline or abnormal quality of life scores.

Current guidelines for decision making about advancement to systemic therapy in severe AD are misunderstood or not used. Treatment has often been reactive with inappropriate use of systemic corticosteroids and unapproved systemic immunosuppressants – drugs that suppress, or reduce, the strength of the body’s immune response. Additionally, international guidelines for treatment differ widely among countries.

In their clinical review, the researchers incorporate national and international guidelines to deliver a comprehensive algorithm to guide clinicians in treating AD patients, as seen in the chart.

 

The steps include:

  • Making a proper diagnosis and defining severity of AD
  • Addressing the basics of AD care:
    • Appropriate skin hydration and use of moisturizers and topical medications
    • Identifying irritants and allergens
    • Treating bacterial, viral or fungal infections
    • Treating psychosocial aspects
    • Developing an action plan
  • Consultations with an AD specialist
  • Considering acute management with wet-wrap therapy
  • Considering hospitalization, treatment with the systemic biologic dupilumab and phototherapy

„Life with severe atopic dermatitis can be incredibly difficult for our patients and their families, and it can be quite challenging to care for. It’s important to let our patients, caregivers, and healthcare providers know that we have entered a new and exciting era in the treatment of AD with a number of targeted therapies approved or being studied which are referenced in this clinical review,“ said Mark Boguniewicz, MD, Professor, Division of Allergy-Immunology and Department of Pediatrics at National Jewish Health and University of Colorado School of Medicine.

 

About the University of Colorado Anschutz Medical Campus

The University of Colorado Anschutz Medical Campus is a world-class medical destination at the forefront of life-changing science, medicine, and healthcare. CU Anschutz serves over 4,500 students and offers more than 40 degree programs through six schools and colleges. We are the single largest health professions education provider in Colorado, awarding over 1,400 degrees annually and home to Children’s Hospital Colorado and UCHealth University of Colorado Hospital. Powered by our award-winning faculty, renowned researchers and a reputation for academic excellence, and with over $500 million in research awards in 2018, the CU Anschutz Medical Campus drives innovation from the classroom to the laboratory to the delivery of unparalleled patient care.

Algorithm for the patient with severe Atopic Dermatitis
Graphic: Annotated algorithm for the patient with severe AD. Credit: CU Anschutz Medical Campus


University of Colorado Anschutz Medical Campus, 15.01.2019 (tB).

Schlagwörter: ,

MEDICAL NEWS

IU School of Medicine researchers develop blood test for anxiety
COVID-19 pandemic increased rates and severity of depression, whether people…
COVID-19: Bacterial co-infection is a major risk factor for death,…
Regenstrief-led study shows enhanced spiritual care improves well-being of ICU…
Hidden bacteria presents a substantial risk of antimicrobial resistance in…

SCHMERZ PAINCARE

Hydromorphon Aristo® long ist das führende Präferenzpräparat bei Tumorschmerz
Sorgen und Versorgen – Schmerzmedizin konkret: „Sorge als identitätsstiftendes Element…
Problem Schmerzmittelkonsum
Post-Covid und Muskelschmerz
Kopfschmerz bei Übergebrauch von Schmerz- oder Migränemitteln

DIABETES

Wie das Dexom G7 abstrakte Zahlen mit Farben greifbar macht…
Diabetes mellitus: eine der großen Volkskrankheiten im Blickpunkt der Schmerzmedizin
Suliqua®: Einfacher hin zu einer guten glykämischen Kontrolle
Menschen mit Diabetes während der Corona-Pandemie unterversorgt? Studie zeigt auffällige…
Suliqua® zur Therapieoptimierung bei unzureichender BOT

ERNÄHRUNG

Positiver Effekt der grünen Mittelmeerdiät auf die Aorta
Natriumaufnahme und Herz-Kreislaufrisiko
Tierwohl-Fleisch aus Deutschland nur mäßig attraktiv in anderen Ländern
Diät: Gehirn verstärkt Signal an Hungersynapsen
Süßigkeiten verändern unser Gehirn

ONKOLOGIE

Strahlentherapie ist oft ebenso effizient wie die OP: Neues vom…
Zanubrutinib bei chronischer lymphatischer Leukämie: Zusatznutzen für bestimmte Betroffene
Eileiter-Entfernung als Vorbeugung gegen Eierstockkrebs akzeptiert
Antibiotika als Störfaktor bei CAR-T-Zell-Therapie
Bauchspeicheldrüsenkrebs: Spezielle Diät kann Erfolg der Chemotherapie beeinflussen

MULTIPLE SKLEROSE

Multiple Sklerose: Aktuelle Immunmodulatoren im Vergleich
Neuer Biomarker für Verlauf von Multipler Sklerose
Multiple Sklerose: Analysen aus Münster erhärten Verdacht gegen das Epstein-Barr-Virus
Aktuelle Daten zu Novartis Ofatumumab und Siponimod bestätigen Vorteil des…
Multiple Sklerose durch das Epstein-Barr-Virus – kommt die MS-Impfung?

PARKINSON

Meilenstein in der Parkinson-Forschung: Neuer Alpha-Synuclein-Test entdeckt die Nervenerkrankung vor…
Neue Erkenntnisse für die Parkinson-Therapie
Cochrane Review: Bewegung hilft, die Schwere von Bewegungssymptomen bei Parkinson…
Technische Innovationen für eine maßgeschneiderte Parkinson-Diagnostik und Therapie
Biomarker und Gene: neue Chancen und Herausforderungen für die Parkinson-Diagnose…